Lung cancer is the leading cause of cancer-related deaths in both men and women in industrialised countries, with a 5-year survival rate of only ∼15%. Histologically, ∼85% of lung cancer patients are classified as non-small cell lung cancer (NSCLC), which are further subdivided into adenocarcinoma (ADC; ∼50%), squamous cell carcinoma (SCC; ∼40%) and other less frequent subtypes ([@bib13]; [@bib11]). Even though both ADC and SCC are epithelial in origin, it is increasingly acknowledged that carcinoma cells need to surround themselves by an aberrant stiff desmoplastic stroma to develop a tumour ([@bib17]; [@bib5]). Likewise, a large body of work indicates that tumour-associated fibroblasts (TAFs), which are the most abundant stromal cell type, are implicated in many critical steps of cancer progression including initiation, growth, invasion, metastasis, stemness, immunosuppression and even resistance to therapies ([@bib23]; [@bib35]; [@bib29]; [@bib27]). Accordingly, targeting the aberrant carcinoma--TAF interactions is emerging as a promising therapeutic strategy in NSCLC and other solid tumours ([@bib35]; [@bib29]).

Nintedanib is a small molecule inhibitor of multiple tyrosine kinases that has been recently approved for second-line treatment after chemotherapy failure combined with the cytotoxic docetaxel in patients with advanced lung ADC, owing to the selective positive therapeutic results reported in ADC (but not in SCC) patients in a phase III clinical trial (LUME-Lung 1) ([@bib38]). Nintedanib (also known as BIBF 1120) competitively binds to the ATP-binding sites within the kinase domains of VEGFR receptors (VEGFR) 1--3, PDGFR *α*/*β*, and FGFR 1--4. In addition, nintedanib inhibits Src family tyrosine kinases (Src, Lck, Lyn), Flt-3 and RET ([@bib18]; [@bib46]; [@bib2]). In agreement with its initial design as a next generation antiangiogenic drug, previous studies with lung cancer xenografts reported that nintedanib exhibits strong antiangiogenic functions through a direct effect on cell types involved in angiogenesis, including endothelial cells, pericytes and smooth muscle cells ([@bib18]). In addition, it was reported that nintedanib exhibits further anticancer effects by reducing tumour growth and metastasis ([@bib18]; [@bib9]). These previous observations highlight the ability of nintedanib to target multiple cell types within the tumour microenvironment, which has been associated with the simultaneous inhibitory effects of this drug on several signalling pathways ([@bib46]; [@bib21]). However, the biological processes underlying both the positive therapeutic effects of nintedanib in ADC and the lack of such effects in SCC remain unknown.

In addition to lung ADC, nintedanib has been recently approved to treat patients with idiopathic pulmonary fibrosis (IPF), based on its ability to slow the progression of this rare disease in clinical trials ([@bib39]; [@bib47]). Although lung ADC and IPF are markedly distinct both clinically and biologically, pulmonary tissues in both diseases have in common an abundant stiff desmoplastic stroma rich in collagen and activated fibroblasts/myofibroblasts ([@bib24]). Because IPF-progression has been strongly associated with the persistent proliferation and pathologic activation of lung fibroblasts ([@bib24]; [@bib47]), analysing the effects of nintedanib on this cell type has been the subject of increasing preclinical research. *In vitro* studies have shown that nintedanib interferes with important fibroblast-dependent hallmarks of lung fibrosis including fibroblast proliferation, activation and deposition of extracellular matrix components in response to pro-fibrotic cytokines like PDGF or TGF-*β* ([@bib47]). These studies clearly indicate that nintedanib has a direct impact on fibroblast functions, thereby suggesting that this drug may also have direct inhibitory effects on TAFs. However, to our knowledge, no studies have been undertaken to examine the impact of nintedanib on activated TAFs.

We have recently shown that ADC-TAFs and SCC-TAFs are activated *in vivo* and overexpress activation markers compared to paired control fibroblasts *in vitro*. Yet ADC-TAFs and SCC-TAFs exhibited also distinct phenotypic alterations in terms of growth regulation and integrin signalling ([@bib36]; [@bib29]). Therefore, given the known direct effects of nintedanib on lung fibroblasts and the distinct aberrant phenotypes of ADC-TAFs and SCC-TAFs, we hypothesised that the selective therapeutic effects of nintedanib on ADC may be due, at least in part, to a larger impact of this drug on ADC-TAFs compared to SCC-TAFs. To test this hypothesis, we examined the inhibitory effects of nintedanib in lung TAFs from ADC and SCC patients as well as lung fibroblast from non-malignant tissue upon stimulation with either growth factors or TGF-*β*1 in terms of growth and activation, respectively. Moreover we examined the potential inhibitory role of nintedanib on the tumour-promoting effects of activated TAFs in terms of growth and invasion in a panel of ADC and SCC cell lines.

Materials and methods
=====================

Tissue samples and primary human lung TAFs
------------------------------------------

Lung tissue samples were obtained from a cohort of 20 early stage NSCLC surgical patients (10 ADC, 10 SCC) prior to 2013 at the *Hospital Clinic de Barcelona* (HCB, Spain) with the approval of the Ethics Committees of the HCB and the *Universitat de Barcelona*. All patients gave their informed consent. Selected patients were male, chemo-naïve, Caucasian, ⩾55 years old, and current smokers with confirmed ADC or SCC diagnosis (additional clinical characteristics of patients are available elsewhere ([@bib45])). Tumour samples were collected and divided into two parts. One part was paraffin-embedded for histologic analysis and the remaining was used to isolate TAFs by outgrowth of tissue explants ([@bib36]). The mesenchymal origin of the primary fibroblasts was confirmed by their positive and negative immunofluorescence staining with vimentin and pan-cytokeratin antibodies, respectively ([@bib45]).

Histology
---------

Immunohistochemical analyses of Ki-67 and *α*-SMA were performed on tissue sections from our cohort using the Bond automated immunohistochemistry system (Leica Microsystems, Wetzlar, Germany) as previously described ([@bib36]; [@bib45]; [@bib29]). Primary antibodies included anti-*α*-SMA (1A4) and anti-Ki-67 (MIB-1, Dako, Cambridge, UK). Nuclei were counterstained with haematoxylin. Histological stainings were imaged with a bright-field microscope (BX43) coupled to a digital camera (DP72) using a × 40 objective (Olympus, Japan). All image processing was carried out with ImageJ ([@bib1]).

Cell culture
------------

The human fibroblast cell line CCD-19Lu obtained from normal pulmonary tissue (ATCC, USA), patient-derived primary lung TAFs and paired fibroblasts from uninvolved pulmonary tissue were maintained in DMEM-based fibroblast culture medium as described elsewhere ([@bib3]; [@bib36]). Data from paired fibroblasts and CCD-19Lu were pooled and used as control fibroblasts based on previous results from our group ([@bib36]). Fibroblasts were used up to passage 10 (CCD-19Lu) or 6 (primary fibroblasts) to avoid replicative senescence ([@bib33]). All experiments with fibroblasts were carried out on tissue culture plastic substrata coated with 0.1 mg ml^−1^ collagen-I solution (Millipore, Billerica, MA, USA) overnight at 4 °C. Unless otherwise indicated, fibroblasts were seeded at 8 × 10^3^ cells cm^−2^. To induce either proliferation or activation, fibroblasts were stimulated with 10% FBS (Gibco, Waltham, MA, USA) or 2.5 ng ml^−1^ human recombinant human TGF-*β*1 (R&D Systems, Minneapolis, MN, USA), respectively, concomitantly with increasing doses of nintedanib. Nintedanib (BIBF 1120) was provided by Boehringer Ingelheim Pharma GmbH & Co (Vienna, Austria), was diluted in DMSO and used at concentrations 0.5--5 *μ*[M]{.smallcaps} based on previous studies ([@bib18]; [@bib46]; [@bib37]; [@bib43]). For flow cytometry experiments, fibroblasts were seeded in fibroblast culture medium for 24 h and maintained in either 0% FBS (serum-free) or 10% FBS medium in the presence of increasing nintedanib doses for 5 days with a media change at day 3.

A panel of lung carcinoma cell lines derived from either ADC (H1437, H522) or SCC (SK-MES-1, H520) (ATCC) patients were used to examine the tumour-promoting effects of TAFs treated with nintedanib. All carcinoma cell lines were wild-type *EGFR* and *KRAS* ([@bib6]) to mimic critical genetic aspects of lung ADC patients that may be treated with nintedanib in the clinic ([@bib8]). Cancer cells were maintained in RPMI-1640-based medium supplemented with 10% of FBS as reported elsewhere (referred to as epithelial culture medium) ([@bib29]).

Conditioned medium
------------------

Fibroblasts were seeded as 8 × 10^3^ cells cm^−2^ in 60 cm^2^ Petri dishes in serum-free fibroblast medium supplemented with 2.5 ng ml^−1^ TGF-*β*1 with our without 2 *μ*[M]{.smallcaps} nintedanib for 3 days. Next, culture medium was washed and replaced with nintedanib-free and serum-free fibroblast culture medium for 48 h. Afterwards, the conditioned medium (CM) was collected, centrifuged to remove suspended cells and stored at −20 °C until use.

Fibroblast cell number density and viability
--------------------------------------------

The number density of viable fibroblasts was assessed with the trypan blue exclusion assay using a hemocytometer ([@bib31]). The percentage of viable fibroblasts was assessed as the ratio of viable cell number density with respect to total cell number density.

Cell cycle analysis
-------------------

DNA histograms of single fibroblasts were obtained by flow cytometry (LSRFortessa, BD Biosciences, San Jose, CA, USA), and the percentages of cycling fibroblasts (i.e., cells in S or G2/M phases) were assessed with FACSDiva Software v6.1.3 (BD Biosciences) as described elsewhere ([@bib36]; [@bib29]).

Quantitative PCR with reverse transcription
-------------------------------------------

RNA extraction and reverse transcription was conducted as previously reported by our group ([@bib45]). Real-time PCR reactions were performed on 20 ng of each cDNA sample using TaqMan Gene Expression Master Mix and TaqMan gene-specific primer pairs and probes (Applied Biosystems, USA) for *COL1A1*, *COL3A1* and *POLR2A* (used as a housekeeping gene). Relative gene expression with respect to the housekeeping gene was assessed as 2^−ΔCt^ ([@bib28]).

Western blotting
----------------

Fibroblasts were lysed in extraction buffer supplemented with phosphatase and protease inhibitors as described before ([@bib36]). Equal protein amounts were separated on a 10% Mini-PROTEAN TGX precast gels (Bio-Rad, Hercules, CA, USA), transferred to a PVDF membrane (GE Healthcare, Little Chalfont, UK), blocked and incubated overnight with suitable primary antibodies including anti-*α*-SMA (Sigma, St Louis, MO, USA), P4HA2 (Proteintech Europe, Manchester, UK) or *β*-actin (Sigma, used as loading control). Protein bands were labelled and visualised by chemiluminescence in a digital imaging system (ImageQuant LAS 4000, GE Healthcare). Protein band intensities were quantified with ImageJ and normalised to the corresponding loading control.

Assessment of *IC*~50~ values describing the antiproliferative and antifibrotic effects of nintedanib in lung fibroblasts
-------------------------------------------------------------------------------------------------------------------------

Selected quantitative assays (fold cell number, *COL1A1* and *COL3A1* expression) were used to compute *IC*~50~ values indicative of the antiproliferative and antifibrotic effects of nintedanib, respectively. For this purpose, the data corresponding to the measurements from each assay (*y*) at different nintedanib concentrations (*x*) were fitted to an exponential decay function (*y*=*y*~*o*~+*a*e^−*b·x*^, where *y*~*o*~, *a* and *b* were the fitting parameters) with SigmaPlot (Systat Software, USA), and used to assess *IC*~50~=*−ln*0.5/*b*. The error *σ*~*IC*50~ associated with the calculation of *IC*~50~ was assessed using error propagation ([@bib44]) as the absolute value of *σ*~*IC*50~=*σ*~*b*~·*ln*0.5/*b*^2^, where *σ*~*b*~ is the uncertainty of the *b* fitting.

Carcinoma cell growth stimulated by CM from TAFs
------------------------------------------------

Carcinoma cell growth stimulated by CM from activated TAFs was assessed using protocols previously described by our group ([@bib29]). Briefly, for each cancer cell line, cancer cells were plated at 1.1 × 10^4^ cells cm^−2^ in six-well plates and grown in 2 ml of a 1 : 1 mixture of CM and serum-free epithelial culture medium for 3 days. A 1 : 1 mixture of serum-free fibroblast/epithelial culture medium was used as (basal) control medium. Afterwards, cells were fixed with 4% PFA and their nuclei counterstained with Hoechst 33342 (Molecular Probes, Eugene, OR, USA). Fluorescent nuclei were imaged and counted with ImageJ. Cell number density was assessed as the average nuclear density/image.

Carcinoma cell invasion stimulated by CM from TAFs
--------------------------------------------------

Cancer cells were seeded on Matrigel-coated filter-inserts as 15 × 10^4^ cells cm^−2^ in serum-free epithelial culture medium as described ([@bib29]). CM or control medium was added to the lower Transwell compartment. After 48 h, cells were fixed with 100% methanol and incubated with 0.5% crystal violet (Sigma). Cells that had invaded into the lower side of the filter were imaged by a phase-contrast microscope provided with a colour camera. Invasion was computed as the average crystal violet positive area/image. All image processing was conducted with ImageJ.

Statistical analysis
--------------------

Two group comparisons were performed with Student's *t*-test (SigmaPlot). Statistical significance was assumed at *P*\<0.05. All experiments were conducted as triplicates. All data shown are mean±s.e.

Results
=======

Nintedanib inhibits both growth and activation of control lung fibroblasts
--------------------------------------------------------------------------

To mimic either a pro-growth or a pro-fibrotic stiff microenvironment *in vitro*, we stimulated fibroblasts cultured on collagen-coated tissue culture plastic with either 10% FBS (which is rich in the fibroblast mitogen PDGF ([@bib14])) or 2.5 ng ml^−1^ of the potent fibroblast activator TGF-*β*1 ([@bib19]), respectively. As expected, such stimulations induced a robust increase in either fibroblast proliferation (10% FBS) or activation (TGF-*β*1) ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). To identify a suitable dose range of nintedanib, we first examined the impact of this drug on the viability and growth of control fibroblasts ([Figure 1](#fig1){ref-type="fig"}). Nintedanib did not compromise the viability of fibroblasts cultured in 10% FBS for 5 days up to 5 *μ*[M]{.smallcaps} ([Figure 1A](#fig1){ref-type="fig"}). In contrast, nintedanib prevented the increase in fibroblast population upon mitogenic stimulation with 10% FBS in a dose-dependent manner ([Figure 1B](#fig1){ref-type="fig"}), whereas DMSO vehicle did not ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). To confirm the antiproliferative effects of nintedanib, we analysed the percentage of cycling fibroblasts by flow cytometry. In qualitative agreement with our fibroblast number density data, nintedanib downregulated the rise in cycling fibroblasts upon stimulation with 10% FBS for 5 days ([Figure 1C](#fig1){ref-type="fig"}). A marked drop in cycling fibroblasts was also observed after only 12 h upon 2 *μ*[M]{.smallcaps} nintedanib treatment, indicating that this drug induces an early growth arrest in fibroblasts ([Figure 1D](#fig1){ref-type="fig"}).

We next examined the antifibrotic effects of nintedanib by assessing the expression of a panel of pro-fibrotic markers including alpha-smooth muscle actin (*α*-SMA), fibrillar collagens (*COL1A1* and *COL3A1*) and prolyl-4-hydroxylase *α* subunit 2 (P4HA2) -- an essential enzyme for collagen biosynthesis that is upregulated by TGF-*β* ([@bib26]; [@bib23]) -- by either western blotting or qRT--PCR ([@bib23]; [@bib19]; [@bib35]) in control fibroblasts stimulated with TGF-*β*1 or DMSO vehicle for 3 days. Nintedanib downregulated the marked induction of both *COL1A1* and *α*-SMA upon concomitant stimulation with TGF-*β*1 in a dose-dependent fashion ([Figure 1E and F](#fig1){ref-type="fig"}), whereas DMSO vehicle did not ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). Likewise nintedanib dose-dependently reduced both *COL3A1* and P4HA2 expression in control fibroblasts ([Figure 1G and H](#fig1){ref-type="fig"}). Remarkably nintedanib even reduced *COL1A1* and *α*-SMA in control fibroblasts pre-activated with TGF-*β*1 for 3 days ([Figure 1I and J](#fig1){ref-type="fig"}). These results underscore the robust inhibitory effects of this drug on the expression of both fibrillar collagens and collagen-related genes. Altogether our results expand previous observations of the antiproliferative and antifibrotic effects of nintedanib in normal and IPF-derived lung fibroblasts ([@bib20]; [@bib46]; [@bib21]; [@bib37]), and reveal that such inhibitory functions are characterised by *IC*~50~ ∼0.8--1 *μ*[M]{.smallcaps} ([Table 1](#tbl1){ref-type="table"}), which is comparable to the maximum nintedanib concentration reported in *in vivo* studies with this drug ([@bib18]).

SCC-TAFs exhibit lower antifibrotic responses to nintedanib than ADC-TAFs, but similar antiproliferative effects
----------------------------------------------------------------------------------------------------------------

Patient-derived lung TAFs overexpress activation markers compared to paired control fibroblasts in both ADC and SCC ([@bib33]; [@bib45]; [@bib29]). Yet we recently reported distinct phenotypic alterations in TAFs from both subtypes, suggesting that they could exhibit subtype-specific responses to nintedanib. To examine this possibility, we first stimulated ADC-TAFs and SCC-TAFs with 10% FBS in the presence of increasing doses of nintedanib or DMSO vehicle. As in control fibroblasts, nintedanib did not compromise the viability of TAFs up to 5 *μ*[M]{.smallcaps} ([Figure 2A](#fig2){ref-type="fig"}). In further agreement with control fibroblasts, nintedanib dose-dependently prevented the increase in both fibroblast number ([Figure 2B](#fig2){ref-type="fig"}) and percentage of cycling fibroblasts ([Figure 2C](#fig2){ref-type="fig"}) upon 10% FBS stimulation, whereas DMSO vehicle did not ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). Such marked impact in the cell cycle could be observed at 12 h upon treatment ([Figure 2D](#fig2){ref-type="fig"}), revealing that nintedanib elicits an early growth arrest also in TAFs. These experiments showed that the antiproliferative effects of nintedanib in TAFs were quantitatively similar in both ADC and SCC, eliciting comparable *IC*~50~ values to each other that were also close to that found in control fibroblasts ([Table 1](#tbl1){ref-type="table"}).

Unlike growth inhibition, even though both ADC-TAFs and SCC-TAFs became activated upon TGF-*β*1 stimulation ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}), nintedanib inhibition of TAF activation in response to TGF-*β*1 was consistently larger in ADC-TAFs than SCC-TAFs in all the pro-fibrotic markers examined (i.e., fibrillar collagens ([Figure 3A and B](#fig3){ref-type="fig"}), *α*-SMA ([Figure 3C](#fig3){ref-type="fig"}) and P4HA2 ([Figure 3D](#fig3){ref-type="fig"})) with statistical significance at different nintedanib concentrations, whereas no expression changes were reported upon treatment with DMSO vehicle ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). Such differential antifibrotic responses in TAFs elicited *IC*~50~ values for *COL1A1* and *COL3A1* that were 2.2- and 1.4-fold higher in SCC-TAFs than ADC-TAFs, respectively ([Table 1](#tbl1){ref-type="table"}). Since *IC*~50~ values for both fibrillar collagens were very similar in ADC-TAFs and control fibroblasts ([Table 1](#tbl1){ref-type="table"}), our data reveal for the first time that SCC-TAFs exhibit a poor antifibrotic response to nintedanib, whereas ADC-TAFs exhibit a normal antifibrotic response to this drug.

Lung TAFs are quiescent and activated *in vivo*, supporting that the subtype-specific antifibrotic function of nintedanib in TAFs may be pathologically relevant
----------------------------------------------------------------------------------------------------------------------------------------------------------------

The marked antiproliferative and antifibrotic responses to nintedanib observed in SCC-TAFs and ADC-TAFs *in vitro* raised the question of what of these effects might be more relevant *in vivo*. To shed light on this issue, we analysed the proliferative and activation status of TAFs in histologic sections from the same patient cohort used to obtain primary TAFs. Our histologic analysis revealed that TAFs are largely negative for the proliferation marker Ki-67 in both ADC and SCC, whereas a substantial fraction of carcinoma cells were Ki-67 positive ([Figure 4](#fig4){ref-type="fig"} and [Supplementary Figure S4](#sup1){ref-type="supplementary-material"}). In contrast, virtually all TAFs were positive for the activation marker *α*-SMA in both ADC and SCC ([Figure 4](#fig4){ref-type="fig"}), in agreement with previous observations from our group ([@bib36]). Because TAFs are largely quiescent and activated in histologic sections, it is conceivable that the differential antifibrotic effects of nintedanib on ADC-TAFs and SCC-TAFs may be more therapeutically relevant than its antiproliferative function.

Nintedanib abrogates the increase in cancer cell growth and invasion elicited by conditioned medium from activated TAFs in ADC but not SCC
------------------------------------------------------------------------------------------------------------------------------------------

To test the latter interpretation, we assessed the inhibitory impact of nintedanib in two critical pro-tumourigenic effects of activated TAFs: stimulation of growth and invasion of carcinoma cells. For this purpose, we stimulated either ADC-TAFs or SCC-TAFs for 3 days with TGF-*β*1 in the presence or absence of 2 *μ*[M]{.smallcaps} nintedanib, which is comparable to the *IC*~50~ for SCC-TAFs ([Table 1](#tbl1){ref-type="table"}), washed the medium, replaced it with nintedanib-free and serum-free fibroblast medium, and collected the corresponding CM as outlined in [Figure 5A](#fig5){ref-type="fig"}. In these conditions, no significant changes in fibroblast number were detected regardless of the presence or absence of nintedanib ([Supplementary Figure S5](#sup1){ref-type="supplementary-material"}). The CM was used to stimulate the growth and invasion of a panel of ADC and SCC cell lines that were selected based on their *EGFR* and *KRAS* wild-type status to mimic key genetic features of those patients that may be treated with nintedanib ([@bib8]). As expected, the CM of activated TAFs induced a robust (∼1.5--2-fold) growth enhancement with respect to serum-free control medium in both ADC and SCC cell lines ([Supplementary Figure S5](#sup1){ref-type="supplementary-material"}). Remarkably, such growth enhancement of carcinoma cells drop by ∼30--40% when using CM from activated TAFs treated with 2 *μ*[M]{.smallcaps} nintedanib in ADC cell lines only ([Figure 5B](#fig5){ref-type="fig"}), whereas it remained virtually unaltered in SCC cells ([Figure 5C](#fig5){ref-type="fig"}). The selective therapeutic effects of nintedanib in ADC cells were even more dramatic when analysing invasion data. Thus, CM of activated TAFs increased markedly (∼1.5--2.5-fold) the invasion through Matrigel-coated Transwell inserts in both ADC and SCC cell lines with respect to serum-free control medium ([Supplementary Figure S5](#sup1){ref-type="supplementary-material"}). In contrast, the observed increase in invasion was reduced by ∼60--70% when using CM from activated TAFs treated with 2 *μ*[M]{.smallcaps} nintedanib in ADC cell lines ([Figure 5D](#fig5){ref-type="fig"}), whereas no reduction was observed in SCC ([Figure 5E](#fig5){ref-type="fig"}). These *in vitro* observations are in qualitative agreement with the selective anticancer effects of nintedanib observed in ADC patients in clinical trials ([@bib38]; [@bib34]). Moreover, these results reveal for the first time that nintedanib *in vitro* induces a robust inhibition of both the growth and invasive advantages provided by soluble factors secreted by activated TAFs in ADC but not SCC.

Finally, to assess the potential contribution of carcinoma cells themselves on the differential therapeutic effects of nintedanib on the carcinoma--TAF cross-talk, we stimulated SCC cells with CM from ADC-TAFs and vice versa. Four different scenarios could be envisioned. Should the observed differential nintedanib responses be attributed largely to TAFs only, then CM of ADC-TAFs treated with nintedanib on SCC cells should induce positive therapeutic responses as in [Figure 5B and D](#fig5){ref-type="fig"}, whereas the opposite experiment (i.e., CM of SCC-TAFs on ADC cells) should induce negative therapeutic responses as in [Figure 5C and E](#fig5){ref-type="fig"}. Conversely, should the observed responses be attributed largely to carcinoma cells, then the outcomes should be inverted (i.e., CM of ADC-TAFs treated with nintedanib on SCC cells should induce negative therapeutic responses, whereas CM of SCC-TAFs on ADC cells should induce positive responses). The results are shown in [Figure 5F and G](#fig5){ref-type="fig"}, where ADC and SCC samples are labelled in blue and red, respectively, to facilitate the experimental interpretation. CM of ADC-TAFs treated with nintedanib on SCC cells elicited negative therapeutic responses in terms of both growth and invasion ([Figure 5F](#fig5){ref-type="fig"}). In contrast, the CM of SCC-TAFs treated with nintedanib on ADC cells elicited a negative response in terms of growth but a positive response in terms of invasion ([Figure 5G](#fig5){ref-type="fig"}). These results support that there is a division of labour between TAFs and carcinoma cells in which both SCC-TAFs and carcinoma cells themselves (ADC and SCC) contribute to the observed differential therapeutic responses to nintedanib.

High nintedanib doses induce vacuolar structures suggestive of autophagy
------------------------------------------------------------------------

During the course of our experiments we observed a consistent formation of large vacuolar structures by phase contrast microscopy in both normal fibroblasts and TAFs in all experimental conditions (10% FBS, TGF-*β*1) at the highest nintedanib concentrations examined (2--5 *μ*[M]{.smallcaps}) ([Supplementary Figure S6](#sup1){ref-type="supplementary-material"}). Similar vacuolar structures have been recently reported in lung fibroblasts treated with nintedanib elsewhere, and have been interpreted as indicators of autophagy induction ([@bib37]). Autophagy is a highly conserved biological process that allows the degradation and recycling of cellular components. This degradative process has been associated with cellular responses to different types of stress ([@bib41]). Accordingly, it is conceivable that high nintedanib concentrations may elicit an autophaghic stress response in both control fibroblasts and TAFs.

Discussion
==========

Nintedanib is a multi-kinase inhibitor initially designed as a next generation antiangiogenic drug ([@bib18]) that has been recently approved to treat patients with advanced lung ADC, based on its selective therapeutic benefits on ADC patients ([@bib38]; [@bib30]). However, the biological processes underlying the selective therapeutic functions of this drug on ADC (but not SCC) had remained undefined. We hypothesised that such selective effects could be due, at least in part, to a larger impact of nintedanib on ADC-TAFs compared to SCC-TAFs. To test this hypothesis we used preclinical *in vitro* models to examine the effects of nintedanib on primary TAFs derived from lung cancer patients and on their tumour-promoting functions on carcinoma cells. To minimise unwanted bias due to sample variability, all TAFs were derived as tissue explants from surgical patients selected upon very stringent criteria. In support to our hypothesis, our results revealed that, in addition to its known antiangiogenic effects ([@bib18]; [@bib9]), nintedanib may be therapeutically effective in ADC owing to its ability to selectively target ADC-TAFs by reducing their activation, which elicits anticancer effects through downregulation of secreted soluble factors in TAFs that stimulate the growth and invasion of carcinoma cells. In agreement with our observations, a significant decrease in activated host fibroblasts was reported in tumour mouse xenografts with ADC cells upon nintedanib treatment, concomitantly with a reduction in tumour size and vessel density ([@bib9]). The remarkable antifibrotic effects of nintedanib are underscored by our novel observation that this drug was able to markedly reduce the expression of activation markers even in pre-activated fibroblasts. Conversely, our data support that the lack of therapeutic benefit of nintedanib in SCC patients is associated with the poor antifibrotic effect of this drug in SCC-TAFs as well as to its failure to reduce the secretion of factors in TAFs that stimulate the growth and invasion of SCC cells. In addition to the direct contribution of TAFs, our mixed CM experiments support that both ADC and SCC cells contribute themselves to the positive therapeutic effects of nintedanib in ADC but not in SCC, revealing a division of labour between TAFs and carcinoma cells in modulating the subtype-specific nintedanib responses.

Our study underscores the need to analyse the differential secretome of ADC-TAFs and SCC-TAFs to ultimately identify those secreted factors that may provide a pro-growth and pro-invasive soluble microenvironment to ADC cells. Likewise an analysis of the potential differential expression of the corresponding receptors in ADC and SCC cells is warranted to shed light on the mechanisms underlying the cross-talk between TAFs and carcinoma cells in the selective therapeutic effects of nintedanib in ADC. Although identifying these mechanisms was beyond the scope of this study, we can envision potential candidates based on previous studies. Specifically TAF stimulation of carcinoma cell growth has been previously associated with numerous secreted growth factors and cytokines such as HGF, FGF, amphiregulin, CXCL12, TNF-*α* or Wnt. Likewise, a variety of cytokines, proteases and pro-migratory extracellular matrix components secreted by TAFs have been implicated in the stimulation of carcinoma cell invasion including TGF-*β*, CTGF, IL-6, MMPs, TIMPs, tenascin or SPARC ([@bib4]; [@bib32]; [@bib7]; [@bib35]). However defining the precise driving factors awaits future investigations.

In addition to the secretion of pro-growth and pro-invasive factors, TAFs may contribute indirectly to tumour progression by hindering the diffusion of cancer therapeutics through increased tortuosity and viscosity ([@bib12]; [@bib15]), owing to the abundant deposition of fibrillar collagens and other fibrotic extracellular matrix components ([@bib19]; [@bib22]; [@bib35]). Remarkably nintedanib downregulated the mRNA levels of the main fibrillar collagens in fibrosis to a larger extent in ADC-TAFs compared to SCC-TAFs. Likewise nintedanib elicited a larger downregulation of P4HA2 expression in ADC-TAFs than in SCC-TAFs, which is an essential enzyme for the intracellular stability of the procollagen triple helix that is required for its effective secretion ([@bib10]; [@bib42]). In agreement with our molecular observations, a recent electron microscopy study reported a downregulation of collagen fibril number and thickness in lung fibroblasts stimulated with TGF-*β*1 in the presence of 1 *μ*[M]{.smallcaps} nintedanib ([@bib25]). Based on these findings, it is conceivable that part of the clinical benefits of the combination of nintedanib with docetaxel in ADC patients are due to the downregulation of fibrillar collagens elicited by nintedanib, for this downregulation may facilitate the delivery of docetaxel to carcinoma cells by removing interstitial barriers that hinder diffusion. In support of this interpretation, we previously reported that the diffusivity of 4 kDa molecules (which is close to the low molecular weight of docetaxel) through type I collagen gels increased by ∼20% upon reducing collagen concentration by ∼70% ([@bib15]), which is a similar reduction to that elicited by 2 *μ*[M]{.smallcaps} nintedanib on *COL1A1* mRNA expression in ADC-TAFs.

ADC-TAFs and SCC-TAFs exhibit distinct phenotypic alterations in terms of growth and integrin signalling in basal conditions (i.e., in the absence of either exogenous pro-growth or pro-activation biochemical stimuli) ([@bib36]). In the present study we increased the list of subtype-specific aberrant features in TAFs by reporting differential antifibrotic responses to nintedanib, and revealed similar responses in ADC-TAFs and control fibroblasts. Although the molecular underpinnings underlying all these subtype-specific alterations in TAFs remains to be elucidated, the differential antifibrotic responses to nintedanib strongly suggest that TAF activation in ADC and SCC elicited by TGF-*β*1 may be regulated through distinct mechanisms. In support to this interpretation we recently showed that the TGF-*β* pathway is globally altered in lung TAFs as part of their epigenetic reprogramming with respect to normal fibroblasts ([@bib45]). In addition two recent studies have reported the nintedanib inhibition of the activity of TGF-*β* receptor II as well as signalling factors of the TGF-*β* pathway in lung fibroblasts stimulated with TGF-*β* ([@bib20]; [@bib37]). Thus, even though the regulatory impact of nintedanib on the TGF-*β* pathway remains incompletely defined ([@bib37]), it is tempting to speculate that the differential antifibrotic effects of nintedanib in ADC-TAFs and SCC-TAFs could be associated with its ability to impact TGF-*β* signalling at different regulatory levels in a subtype-specific fashion.

In addition to antifibrotic functions, nintedanib exhibited robust antiproliferative effects in both normal lung fibroblasts and TAFs when stimulated with 10% serum, which is rich in PDGF and other fibroblast mitogens ([@bib14]). These findings are consistent with previous observations that nintedanib efficiently blocks PDGFR activation and proliferation in normal and fibrotic fibroblasts *in vitro* and *in vivo* ([@bib20]; [@bib46]; [@bib21]), and altogether reveal that this drug elicits strong antiproliferative functions on lung fibroblasts in both normal and diseased conditions. However, although such antiproliferative effects appear to be relevant in IPF and other fibrotic disorders, we argue that the therapeutically relevant function of nintedanib against the desmoplastic tumour stroma in ADC is its antifibrotic rather than its antiproliferative effects, because TAFs are largely quiescent and activated *in vivo*.

The highest nintedanib dose used in our study (5 *μ*[M]{.smallcaps}) induced the formation of large vacuolar structures in both normal lung fibroblasts and lung TAFs. Similar structures have been recently reported in lung fibroblasts treated with increasing doses of nintedanib up to 2 *μ*[M]{.smallcaps} elsewhere, and were directly associated with autophagy ([@bib37]). In contrast, it is currently unclear whether nintedanib induces vacuolar structures or autophagy in lung cancer cells ([@bib47]; [@bib43]), although autophagy has been reported in different cancer types in response to other tyrosine kinase inhibitors ([@bib16]; [@bib40]). Because previous work has associated autophagy with cell responses to different types of stress ([@bib41]), it is conceivable that fibroblast autophagy is a stress response triggered by high nintedanib doses. However, even though the 2--5 *μ*[M]{.smallcaps} range is larger than the maximum nintedanib concentration reported in plasma (∼1 *μ*[M]{.smallcaps}) during *in vivo* studies of this drug in tumour xenografts ([@bib18]), it remains unknown whether stromal autophagy does occur in patients.

Our observed direct inhibitory effect of nintedanib on the activation and tumour-promoting effects of ADC-TAFs expand previous observations of a direct inhibitory effect of this drug on stromal cell types involved in angiogenesis ([@bib18]). Collectively these observations underscore that nintedanib can be considered an anti-stromal drug, for it inhibits multiple tumour-promoting processes by targeting numerous cell types within the tumour stroma. Accordingly, the synergistic therapeutic effects of nintedanib combined with docetaxel reported in ADC patients illustrate an emerging strategy in cancer therapeutics based on combining drugs that target the aberrant tumour stroma with either cytotoxic drugs or targeted drugs against carcinoma cells ([@bib32]; [@bib7]; [@bib35]). However, it should be borne in mind that the latter therapeutic strategy was unsuccessful in SCC patients, supporting that the aberrant carcinoma--TAF cross-talk in SCC is mediated through distinct mechanisms than in ADC. Yet, because our preclinical models of carcinoma--TAF interactions captured the selective therapeutic effects of nintedanib in ADC (but not SCC) reported in clinical trials, we argue that these models may be useful in identifying the mechanisms underlying the poor antifibrotic response of SCC-TAFs to nintedanib.

In summary, our preclinical study reveals that the selective therapeutic benefits of nintedanib combined with docetaxel in ADC are associated with at least two complementary processes. First, the direct antifibrotic effect of nintedanib on ADC-TAFs, which reduces the deposition of fibrillar collagens, thereby potentially reducing the physical barriers that may hinder the delivery of docetaxel to cancer cells. Second, the reduction of the secretion of yet unidentified soluble factors that stimulate the growth and invasion of ADC cells. Likewise, our results support that the latter therapeutic benefits of nintedanib are largely absent in SCC due to the poor antifibrotic response of SCC-TAFs to this drug. Collectively these results underscore the important role of TAFs in modulating therapy responses.
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![**Antiproliferative and antifibrotic effects of nintedanib in control lung fibroblasts.** (**A**) Percentage of viable fibroblasts cultured with 10% FBS for 5 days with increasing concentrations of nintedanib (*n*=3). (**B** and **C**) Fold cell number (**B**, *n*=5) and percentage of cycling cells (i.e., cells in S or G2/M) (**C**, *n*=4) of fibroblasts cultured as in **A**. Continuous line in **B** corresponds to the fitting of an exponential decay function that was used to assess *IC*~50~ shown in [Table 1](#tbl1){ref-type="table"}. (**D**) Percentage of cycling fibroblasts cultured for 12 h with 10% FBS in the absence or presence of 2 *μ*[M]{.smallcaps} nintedanib (*n*=3). (**E**) Fold mRNA expression of *COL1A1* in fibroblasts stimulated with 2.5 ng ml^−1^ TGF-*β*1 for 3 days with increasing concentrations of nintedanib (*n*=5). (**F**) Left, representative western blot analysis of *α*-SMA and *β*-actin (loading control) of fibroblasts cultured as in **E**. Right, densitometry analysis of *α*-SMA expression normalised to *β*-actin (*n*=5). (**G** and **H**) Fold mRNA expression of *COL3A1* (**G**) and western blot analysis of P4HA2 (**H**) in fibroblasts cultured as in (**E**) (*n*=4). (**I** and **J**) Expression of *COL1A1* and *α*-SMA in fibroblasts pre-activated with 2.5 ng ml^-1^ TGF-*β*1 for 3 days and subsequently treated with 2.5 ng ml^−1^ TGF-*β*1 in the absence or presence of 2 *μ*[M]{.smallcaps} nintedanib (*n*=3). Continuous lines in (**E**, **G** and **I**) correspond to fittings of an exponential decay function, which elicited *IC*~50~ values shown in [Table 1](#tbl1){ref-type="table"} (for **E** and **G**) and 0.74 *μ*[M]{.smallcaps} for **I**. \**P*⩽0.05, \*\**P*⩽0.01 and \*\*\**P*⩽0.005 with respect to 0 *μ*[M]{.smallcaps} nintedanib were determined by Student's *t*-test.](bjc2017270f1){#fig1}

![**Antiproliferative effects of nintedanib in ADC-TAFs and SCC-TAFs.** (**A**) Viability of TAFs cultured with 10% FBS for 5 days in the presence of increasing nintedanib concentrations (*n*=3 ADC, 3 SCC). (**B**--**D**) Antiproliferative effects of nintedanib were assessed in terms of fold TAF number (**B**; *n*=3 ADC, 3 SCC) and percentage of cycling TAFs (**C**; *n*=5 ADC, 4 SCC) as in [Figure 1](#fig1){ref-type="fig"}. (**D**) Percentage of cycling TAFs (*n*=2 ADC, 2 SCC; pooled) after 12 h in the presence or absence of 2 *μ*[M]{.smallcaps} nintedanib. Continuous lines in **B** and **C** correspond to fittings to an exponential decay function, which were used to assess *IC*~50~ values shown in [Table 1](#tbl1){ref-type="table"}. \**P*⩽0.05, \*\**P*⩽0.01 and \*\*\**P*⩽0.005 with respect to 0 μ[m]{.smallcaps} nintedanib were determined by Student\'s *t*-test.](bjc2017270f2){#fig2}

![**Antifibrotic effects of nintedanib in ADC-TAFs and SCC-TAFs.** Antifibrotic effects were assessed in terms of expression of a panel of activation markers including fibrillar collagens *COL1A1* (**A**; *n*=6 ADC, 8 SCC) and *COL3A1* (**B**; *n*=6 ADC, 7 SCC), *α*-SMA (**C**; *n*=6 ADC, 6 SCC) and P4HA2 (**D**; *n*=5 ADC, 5 SCC) upon stimulation with 2.5 ng ml^−1^ TGF-*β*1 for 3 days in the presence of increasing nintedanib concentrations as in [Figure 2](#fig2){ref-type="fig"}. Continuous lines in (**A** and **B**) correspond to fittings to an exponential decay function, which were used to assess *IC*~50~ values shown in [Table 1](#tbl1){ref-type="table"}. \#*P*⩽0.05 and \#\#\#*P*⩽0.005 in ADC-TAFs compared to SCC-TAFs, as determined by Student's *t*-test. \**P*⩽0.05 and \*\*\**P*⩽0.005 with respect to 0 μ[m]{.smallcaps} nintedanib were determined by Student\'s *t*-test.](bjc2017270f3){#fig3}

![**Proliferative and activation status of TAFs *in vivo*.** Illustrative images of Ki-67 and *α*-SMA stromal stainings in histologic sections from ADC and SCC patients obtained with a × 40 objective. Arrowheads point to spindle-shaped nuclei characteristic of fibroblasts. Additional images from other patients are shown in [Supplementary Figure S4](#sup1){ref-type="supplementary-material"}.](bjc2017270f4){#fig4}

![**Nintedanib modulation of the tumour-promoting effects of activated TAFs.** (**A**) Outline of the experimental design used to assess the growth (top right) and invasion (bottom right) of carcinoma cell lines stimulated with conditioned medium (CM) from TAFs activated with 2.5 ng ml^−1^ TGF-*β*1 for 3 days in the presence or absence of 2 *μ*[M]{.smallcaps} nintedanib and subsequently maintained in serum-free and nintedanib-free medium for 2 days. (**B** and **C**) Average fold cell number per field of a panel of wild-type (wt) *EGFR* and *KRAS* carcinoma cell lines derived from ADC (H1437, H522) (**B**) or SCC (SK-MES-1, H520) (**C**) patients upon stimulation with CM from ADC-TAFs (*n*⩾4) or SCC-TAFs (*n*⩾4), respectively, obtained as described in **A**. (**D** and **E**) Average fold invasion of the same panel of ADC (**D**) or SCC (**E**) carcinoma cell lines induced by different types of CM (*n*⩾4 for ADC-TAFs and SCC-TAFs) as in (**B** and **C**). (**F**) Growth and invasion of SCC cells (H520) induced by the CM of ADC-TAFs (*n*=3). (**G**) Growth and invasion of ADC cells (H1437) induced by the CM of SCC-TAFs (*n*=3). \**P*⩽0.05 and \*\*\**P*⩽0.005 with respect to 0 μ[m]{.smallcaps} nintedanib were determined by Student\'s *t*-test.](bjc2017270f5){#fig5}

###### Nintedanib *IC*~50~ (*μ*[M]{.smallcaps}) values characterising the antiproliferative and antifibrotic effects on control fibroblasts and TAFs (mean±s.e.)

  **Assay**       **Control fibroblasts**   **ADC-TAFs**   **SCC-TAFs**
  --------------- ------------------------- -------------- --------------
  Proliferation   0.93±0.09                 0.96±0.09      1.09±0.05
  *COL1A1*        1.1±0.3                   1.05±0.07      2.3±0.6
  *COL3A1*        0.80±0.03                 0.74±0.15      1.0±0.1

Abbreviations: ADC=adenocarcinoma; SCC= squamous cell carcinoma; TAF=tumour-associated fibroblasts.

*IC*~50~ (*μ*[M]{.smallcaps}) values were computed from [Figure 1B, E and G](#fig1){ref-type="fig"} (control fibroblasts) and [Figures 2B](#fig2){ref-type="fig"} and [3A](#fig3){ref-type="fig"} and [B](#fig3){ref-type="fig"} (TAFs).
